Alpha-Glucosidase Inhibitors Market
According to Intent Market Research, the Alpha-glucosidase Inhibitors Market is expected to grow from USD 3.7 billion in 2023 at a CAGR of 6.3% to touch USD 5.7 billion by 2030. The Alpha-glucosidase Inhibitors Market is dominated by key players such as Merck & Co., Inc., Boehringer Ingelheim International GmbH, Sanofi S.A., Eli Lilly and Co., Novo Nordisk, Bristol Myers Squibb, Teva Pharmaceuticals, Takeda Pharmaceutical Company Limited, Mylan N.V. (now part of Viatris Inc.), Zydus Cadila, Astellas Pharma Inc., AbbVie Inc., Pfizer Inc., Amgen Inc., Hikma Pharmaceuticals.